Key Stats for Regeneron Stock
- Past-Week Performance: -1.8%
- 52-Week Range: $4766.5 to $821.1
- Current Price: $756.9
What Happened?
Regeneron (REGN), a biotech whose revenue engine runs on blockbuster antibody drugs, is building a credible second growth act just as its core franchise faces biosimilar pressure, with the stock at $756.91 against a 52-week high of $821.11.
On March 9, Hansoh Pharmaceutical’s Phase 3 trial of olatorepatide, a once-weekly weight-loss injection Regeneron holds global rights to outside China, delivered up to 19% mean body-weight loss at week 48 with favorable GI tolerability, triggering a 2% share gain to $774.29 on March 10.
Dupixent, Regeneron’s antibody treating type 2 inflammatory diseases including eczema, asthma, and nasal polyps, posted $4.9B in Q4 global net sales, up 32% year over year, while the February 24 FDA approval for allergic fungal rhinosinusitis expanded its approved U.S. indication count to nine.
George Yancopoulos, President and Chief Scientific Officer, stated on the Q4 2025 earnings call that “we are developing next-generation agents specifically targeting IgE-producing cells with the first expected to enter clinical development over the next year for potentially more rapid and broader allergy applications,” underscoring a pipeline strategy that extends well beyond Dupixent’s current label.
The Sanofi development balance, a profit-sharing obligation that has reduced Regeneron’s take-home collaboration revenue, is on track for full repayment by mid-2026, at which point the company captures its full share of Dupixent’s global profits, adding roughly $1.2B in annualized revenue directly to the bottom line alongside a global Phase 3 launch of olatorepatide and at least four FDA approval decisions expected in 2026.
Wall Street’s Take on REGN Stock
The olatorepatide Phase 3 result on March 9 reframes Regeneron’s earnings story, adding a credible obesity growth vector to a base business already set to inflect sharply as the Sanofi development balance, a profit-sharing obligation that has suppressed collaboration revenues, clears by mid-2026.
TIKR consensus estimates show REGN EPS normalized essentially flat at $44.79 in 2026E versus $44.31 in 2025A, masking the real story: once the Sanofi balance repays and Dupixent’s full $17.8B annual revenue run rate flows unencumbered, EPS is projected to accelerate to $52.81 in 2027E, a 17.9% jump, and $60.92 in 2028E, a further 15.4% gain, supported by Libtayo’s adjuvant CSCC launch and Lynozyfic building share in multiple myeloma.
Eli Lilly (LLY), the benchmark large-cap biotech competing directly in obesity, is forecast to grow normalized EPS 43.2% in 2026E before decelerating to 21.0% in 2027E, while REGN’s EPS growth rate of 17.9% in 2027E and 15.4% in 2028E closes that gap materially, yet REGN trades at a steep valuation discount to LLY, making the risk-reward asymmetry difficult to ignore.
Seventeen analysts currently cover REGN, with 17 buys, 3 outperforms, 8 holds, and 1 underperform; the mean price target of $872.85 implies 15.3% upside from the current $756.91, a consensus that reflects the Dupixent franchise and existing pipeline but almost certainly does not yet price olatorepatide’s global Phase 3 launch.
The spread between the street’s low target of $730 and high of $1,057 is wide enough to matter: the bear case essentially prices continued biosimilar erosion of EYLEA 2mg accelerating in the second half of 2026, while the $1,057 bull case requires fianlimab, Regeneron’s LAG-3 antibody in melanoma, to deliver a best-in-class Phase 3 result in the first half of 2026 on top of the Dupixent and olatorepatide theses.
What Does the Valuation Model Say?
TIKR’s mid-case model prices REGN at $1,245.76 by December 2030, implying a 64.6% total return at a 10.9% annualized IRR, built on a 7.7% revenue CAGR and a net income margin recovery from 34.1% in 2025A to 37.6% in the mid-case, a trajectory supported directly by the Sanofi balance repayment and operating leverage on a portfolio that now spans nine approved Dupixent indications.
The market is pricing REGN as a Dupixent-dependent franchise under biosimilar siege, but the 2027 EPS inflection to $52.81 reflects a business that has already diversified across three commercial blockbusters and is adding a fourth growth vector in obesity before EYLEA’s biosimilar impact peaks.
That $52.81 2027E EPS figure is not speculative: it is underwritten by the Sanofi balance repayment confirmed for mid-2026, Libtayo’s adjuvant CSCC launch already added to NCCN Category 1 guidelines, and TIKR’s mid-case target of $1,245.76 assumes no contribution from olatorepatide or fianlimab at all.
CFO Chris Fenimore stated at the TD Cowen conference on March 4 that the company has “around $19 billion in cash” with no obligation to deploy it at stretched valuations, signaling a management team that will buy back stock aggressively if the discount persists.
The key risk is EYLEA HD: if the prefilled syringe decision expected in late April disappoints or biosimilar EYLEA 2mg share loss accelerates faster than the HD conversion offsets it, the 83% to 84% gross margin guidance for 2026 comes under pressure and the EPS inflection timeline shifts right.
The single event to watch is the fianlimab first-line metastatic melanoma Phase 3 readout, expected in the first half of 2026; a positive result confirming the 57% objective response rate and 24-month median PFS seen in Phase 1 would force a street-wide reassessment of a pipeline that the current $756.91 price is not paying for.
Should You Invest in Regeneron Pharmaceuticals, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up REGN stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Regeneron Pharmaceuticals, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze REGN stock on TIKR for Free →
